Focus Stocks
Keller Rohrback L.L.P. Announces Investigation of Pfizer, Inc. Regarding the Lo/Ovral®-28 and Norgestrel Birth Control Pill Recall
Published on Friday, 03 February 2012 18:40 Written by TradersHuddle Staff
SEATTLE-( Business Wire )-Attorney Advertising. Keller Rohrback L.L.P. (www.krcomplexlit.com) is investigating possible consumer claims against Pfizer, Inc. (NYSE: PFE) relating to its recent recall of certain lots of Lo/Ovral®-28 and Norgestrel birth control pills that were sold in the U.S. This investigation focuses on the expenses incurred by consumers as a result of the recalled birth control pills, such as the cost of the pills, back-up methods of birth control, pregnancy tests, and/or consultations with a physician, as recommended by Pfizer, due to this recall.
On January 31, 2012, Pfizer voluntarily recalled approximately 1 million packets of the Lo/Ovral®-28 Tablets (norgestrel and ethinyl estradiol) and the Norgestrel and Ethinyl Estradiol Tablets (generic). The packets of birth control pills typically have 21 tablets that contain active ingredients and seven tablets of inert ingredients or “placebo” pills. However, the recalled birth control packs may contain the wrong number of each type of tablet and the tablets may be out of sequence. According to a Pfizer news release, “As a result of this packaging error, the daily regimen for these oral contraceptives may be incorrect and could leave women without adequate contraception, and at risk for unintended pregnancy.” Pfizer recommends that women who have used Lo/Ovral®-28 or Norgestrel pills over the last several months should consult with their doctor and begin using a non-hormonal birth control method immediately.
If you were prescribed Lo/Ovral®-28 or Norgestrel birth control pills that are the subject of the recall and paid money as a result, or if you would like more information regarding our investigation, please contact paralegal Maggie Norton or attorneys Havila Unrein, Sharon Hritz or Gretchen Freeman Cappio at (800) 776-6044 or via email at This e-mail address is being protected from spambots. You need JavaScript enabled to view it. .
Keller Rohrback, with offices in Seattle, Phoenix, New York and Santa Barbara, is proud to offer its expertise in consumer cases to clients nationwide.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.
Related Articles
- FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer’s Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
- Pfizer Names Olivier Brandicourt as President and General Manager, Emerging Markets and Established Products Business Units
- Pfizer Teams With EatingWell To Launch Free Mobile App
- Pfizer Invites Public to View and Listen to Webcast of June 3 Pfizer Analyst and Investor Meeting at ASCO
- Pfizer Exploratory Study Measures Effects Of Lyrica (pregabalin) On Brain Activity In Fibromyalgia Patients
- Pfizer Is Near its 50 Day Moving Average
- High Above Average Volume on Pfizer
- Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC)
- Pfizer High Volume Day?
- Pfizer High Volume Day?
Related Partner Headlines
- Pfizer Inc (PFE): Today's Featured Drugs Loser - TheStreet.com
- Pfizer Inc (PFE): Today's Featured Drugs Loser - TheStreet.com
- UPDATE: Pfizer Says Didn't Meet Primary Endpoint - Benzinga
- Dow Today: Pfizer (PFE) Higher - TheStreet.com
- UPDATE: Pfizer Announces FDA Arthritis Advisory Committee Recommends Approval of Tofacitinib - Benzinga
- Pfizer Stock To Go Ex-dividend Tomorrow (PFE) - TheStreet.com
- UPDATE: Pfizer Announces New Long-Term Relapse Prevention Data For PRISTIQ® (desvenlafaxine) 50 mg/day For The Treatment Of Major Depressive Disorder In Adults - Benzinga
- Pfizer Inc (PFE): Today's Featured Drugs Loser - TheStreet.com
- Future of Pfizer: It's the R&D, Stupid! - TheStreet.com
- Dow Today: Travelers Companies (TRV) Leads The Day Higher, Pfizer (PFE) Lags - TheStreet.com
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
The Global Retrenchment Accelerates - TheStreet.com -
Bain Capital Sent 0,000-Plus to Obama and Dems in 2008 - TheStreet.com -
Market Preview: Low-Grade Uncertainty - TheStreet.com -
The EPA's Dangerous Game - TheStreet.com -
Sticking with the Preferred Plan - TheStreet.com -
Infoblox Posts Blowout Earnings; Shares Rise - TheStreet.com -
CNH Global NV (CNH): Today's Featured Industrial Loser - TheStreet.com -
Warner Chilcott PLC (WCRX): Today's Featured Health Care Loser - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,529.75 Trade time:4:05PM EDT Value change:▲33.60 (0.27%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,320.68 Trade time:4:32PM EDT Value change:▲1.82 (0.14%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,839.38 Trade time:5:16PM EDT Value change:▼10.74 (-0.38%)In The Wires
-
Photo Release -- Cars For a Living: The World's First High-Octane Business Podcast -
Internal Fixation Systems, Inc. Enters Into $7.5M Equity Purchase Agreement With Hyde Park Advisors, LLC, an Affiliate of Institutional Investor Central Park Financial -
Sims Metal Management Market Update for Fiscal 2012 -
Block & Leviton LLP reminds investors that deadline to seek a lead plaintiff position in Swisher Hygiene Inc. is May 29, 2012; informs of expanded Class Period -
Maple and TMX Group note publication by British Columbia Securities Commission of draft recognition order and undertakings -
PDI, Inc. Announces New Business Win Valued at $57 Million -
Neuberger Berman Real Estate Securities Income Fund Inc. Announces Plan to Redeem its Auction Market Preferred Shares -
Ryan & Maniskas, LLP Announces Investigation of Skechers USA Inc.









